Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

Francesca J. Torriani, Maribel Rodriguez-Torres, Jürgen K. Rockstroh, Eduardo Lissen, Juan Gonzalez-García, Adriano Lazzarin, Giampiero Carosi, Joseph Sasadeusz, Christine Katlama, Julio Montaner, Hoel Sette, Sharon Passe, Jean De Pamphilis, Frank Duff, Uschi Marion Schrenk, Douglas T. Dieterich

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV. METHODS: A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 μg per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plus ribavirin. Patients were treated for 48 weeks and followed for an additional 24 weeks. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72). RESULTS: The overall rate of sustained virologic response was significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 percent, P

Original languageEnglish
Pages (from-to)438-450
Number of pages13
JournalNew England Journal of Medicine
Volume351
Issue number5
DOIs
Publication statusPublished - Jul 29 2004

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients'. Together they form a unique fingerprint.

  • Cite this

    Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., Sette, H., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U. M., & Dieterich, D. T. (2004). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351(5), 438-450. https://doi.org/10.1056/NEJMoa040842